SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:DiVA.org:uu-318840"
 

Sökning: onr:"swepub:oai:DiVA.org:uu-318840" > Current Status of R...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00003453naa a2200433 4500
001oai:DiVA.org:uu-318840
003SwePub
008170330s2017 | |||||||||||000 ||eng|
024a urn:nbn:se:uu:diva-3188402 urn
024a https://doi.org/10.3390/ph100100302 DOI
040 a (SwePub)uu
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a for2 swepub-publicationtype
100a Fani, Melpomeniu Division of Radiopharmaceutical Chemistry, University Hospital of Basel, 4031 Basel, Switzerland4 aut
2451 0a Current Status of Radiopharmaceuticals for the Theranostics of Neuroendocrine Neoplasms
264 1c 2017
338 a electronic2 rdacarrier
506 a gratis
520 a Nuclear medicine plays a pivotal role in the management of patients affected by neuroendocrine neoplasms (NENs). Radiolabeled somatostatin receptor analogs are by far the most advanced radiopharmaceuticals for diagnosis and therapy (radiotheranostics) of NENs. Their clinical success emerged receptor-targeted radiolabeled peptides as an important class of radiopharmaceuticals and it paved the way for the investigation of other radioligand-receptor systems. Besides the somatostatin receptors (sstr), other receptors have also been linked to NENs and quite a number of potential radiolabeled peptides have been derived from them. The Glucagon-Like Peptide-1 Receptor (GLP-1R) is highly expressed in benign insulinomas, the Cholecystokinin 2 (CCK2)/Gastrin receptor is expressed in different NENs, in particular medullary thyroid cancer, and the Glucose-dependent Insulinotropic Polypeptide (GIP) receptor was found to be expressed in gastrointestinal and bronchial NENs, where interestingly, it is present in most of the sstr-negative and GLP-1R-negative NENs. Also in the field of sstr targeting new discoveries brought into light an alternative approach with the use of radiolabeled somatostatin receptor antagonists, instead of the clinically used agonists. The purpose of this review is to present the current status and the most innovative strategies for the diagnosis and treatment (theranostics) of neuroendocrine neoplasms using a cadre of radiolabeled regulatory peptides targeting their receptors.
653 a CCK2
653 a GIP
653 a GLP-1R
653 a exendin-4
653 a gastrin
653 a neuroendocrine neoplasms
653 a radiolabeled peptides
653 a somatostatin receptor antagonists
653 a theranostics
700a Peitl, Petra Kolencu Department of Nuclear Medicine, University Medical Centre Ljubljana, 1000 Ljubljana, Slovenia4 aut
700a Velikyan, Irina,d 1966-u Uppsala universitet,Radiologi,Preparativ läkemedelskemi4 aut0 (Swepub:uu)irinveli
710a Division of Radiopharmaceutical Chemistry, University Hospital of Basel, 4031 Basel, Switzerlandb Department of Nuclear Medicine, University Medical Centre Ljubljana, 1000 Ljubljana, Slovenia4 org
773t Pharmaceuticalsg 10:1q 10:1x 1424-8247
856u https://doi.org/10.3390/ph10010030y Fulltext
856u http://uu.diva-portal.org/smash/get/diva2:1085898/FULLTEXT01.pdfx primaryx Raw objecty fulltext:print
856u https://www.mdpi.com/1424-8247/10/1/30/pdf
8564 8u http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-318840x lärosäteslänky Till lärosätets (uu) databas
8564 8u https://doi.org/10.3390/ph10010030

Hitta via bibliotek

Till lärosätets databas

Hitta mer i SwePub

Av författaren/redakt...
Fani, Melpomeni
Peitl, Petra Kol ...
Velikyan, Irina, ...
Artiklar i publikationen
Pharmaceuticals
Av lärosätet
Uppsala universitet

Sök utanför SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy